These findings provide compelling evidence that AMP-IBP5 shows its beneficial effects in psoriasis via LRP1-dependent mechanisms, highlighting LRP1 as a therapeutic target in the treatment of psoriasis. This evidence concerns the gene LRP1 and psoriasis.